Conor Cobalt Chromium Reservoir Based Stent With Sirolimus Elution in Native Coronary Artery Lesions (NEVO RES-II)
A Prospective, Multi-Center Study of the Conor Cobalt Chromium Reservoir Based Stent (NevoTM) With Sirolimus Elution in Native Coronary Artery Lesions (NEVO RES-II)
Sponsor: Conor Medsystems
Terminated
The NEVO™ stent will not be commercialized. Cordis decided to close the study after 3 years. This decision took the absence of safety signals into account.
Other terminated trials from Conor Medsystems
Other Coronary Disease trials with similar outcome
A PHASE2 clinical study on Coronary Disease, this trial is terminated or withdrawn. The trial is conducted by Conor Medsystems and has accumulated 10 data snapshots since 2008. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
10 versions recorded-
Dec 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Dec 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
▶ Show 5 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE2
-
Jun 2018 — Nov 2020 [monthly]
Terminated PHASE2
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE2
-
Aug 2017 — May 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Aug 2017 [monthly]
Terminated PHASE2
First recorded
Jun 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Conor Medsystems
- Cordis US Corp.
For direct contact, visit the study record on ClinicalTrials.gov .